61 completed, 4 unknown, 2 terminated. 31 Phase 3, 21 Phase 2, 7 Phase 1, 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 31 | Completed 30, Terminated 1 |
| Phase 2 | 21 | Completed 19, Terminated 1, Unknown 1 |
| Phase 1 | 7 | Completed 7 |
| Phase 4 | 4 | Completed 3, Unknown 1 |
Follow paritaprevir: new trials by email Literature Review of paritaprevir trials Research Report on paritaprevir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C Direct-acting antiviral agents - Hepatitis C, Chronic | Unknown | Qing XIe | 300 | 2019-03-06 | 2021-07-07 | |
| Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet - End-stage Renal Disease, HCV Coinfection | Phase 4 | Completed | Assiut University | 110 | 2018-05-01 | 2020-01-10 |
| Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients SOF plus (OBV/PTV/r) plus RBV - Chronic Hepatitis C Virus Infection | Phase 1 / Phase 2 | Completed | Beni-Suef University | 113 | 2017-03-01 | 2020-05-18 |
| Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks ombitasvir/paritaprevir/ritonavir 8 weeks, dasabuvir 8 weeks - Hepatitis C Infection | Completed | Hepa C | 200 | 2017-02-20 | 2018-05-21 | |
| Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4 OBV/PTV/r) ± ribavirin (RBV) - Hepatitis C Virus Infection | Phase 1 / Phase 2 | Completed | Beni-Suef University | 100 | 2017-01-05 | 2020-05-12 |
| Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis Patients Ombitasvir, Paritaprevir and Ritonavir - Chronic Hepatitis c | Phase 2 | Unknown | Ain Shams University | 40 | 2016-11-09 | 2018-01-18 |
| Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C | Completed | AbbVie | 256 | 2016-07-07 | 2019-10-11 | |
| Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P Paritaprevir/ritonavir/ombitasvir, Dasabuvir, Ribavirin - Hepatitis C, Acute | Phase 3 | Completed | Kirby Institute | 83 | 2016-06-01 | 2022-08-22 |
| Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C Paritaprevir/ritonavir/ombitasvir, Dasabuvir, Ribavirin - Chronic Hepatitis C | Completed | AbbVie | 216 | 2016-04-05 | 2019-03-15 | |
| A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin - Chronic Hepatitis C | Phase 4 | Completed | American Research Corporation | 100 | 2016-03-01 | 2018-10-18 |
| A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection ABT-493/ABT-530, OBV/PTV/r - Chronic Hepatitis C Virus, Hepatitis C Virus | Phase 3 | Completed | AbbVie | 295 | 2016-02-22 | 2021-07-16 |
| A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults ombitasvir/paritaprevir/ritonavir, dasabuvir - Hepatitis C Infection, Hepatitis C Virus | Phase 3 | Completed | AbbVie | 166 | 2015-11-24 | 2021-07-30 |
| The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C | Completed | AbbVie | 101 | 2015-11-05 | 2019-05-06 | |
| A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C Infection | Phase 2 / Phase 3 | Completed | AbbVie | 64 | 2015-10-28 | 2021-10-05 |
| Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection ombitasvir/paritaprevir/ritonavir and dasabuvir, ribavirin - Hepatitis C Virus (HCV) | Phase 3 | Completed | AbbVie | 105 | 2015-10-28 | 2019-12-10 |
| Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C | Completed | AbbVie | 565 | 2015-10-13 | 2019-03-27 | |
| Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C, Genotype 1 or 4 | Completed | AbbVie | 314 | 2015-10-07 | 2019-05-06 | |
| Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease ombitasvir/paritaprevir/ritonavir and dasabuvir, ombitasvir/paritaprevir/ritonavir - Hepatitis C Virus (HCV) | Phase 3 | Completed | AbbVie | 18 | 2015-09-30 | 2017-12-04 |
| Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV) - HIV Infections, Hepatitis C | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 46 | 2015-09-16 | 2021-11-04 |
| Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects ABT-450/r/ABT-267, ABT-333 - Healthy Volunteer | Phase 1 | Completed | AbbVie | 18 | 2015-09-01 | 2015-10-19 |
Showing 20 of 67. Sign in to see all of them.
Hepatitis C (52) · Hepatitis C, Chronic (39) · Fibrosis (7) · Acquired Immunodeficiency Syndrome (2) · HIV Infections (2) · Hepatitis, Chronic (2) · Kidney Diseases (2) · Kidney Failure, Chronic (2) · Renal Insufficiency (2) · Infections (1) · Renal Insufficiency, Chronic (1)
AbbVie (37) · AbbVie (prior sponsor, Abbott) (15) · Abbott (3) · Beni-Suef University (2) · Ain Shams University (1) · American Research Corporation (1) · Assiut University (1) · Hepa C (1) · Kirby Institute (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Nova Scotia Health Authority (1) · Qing XIe (1) · Tanta University (1) · Valme University Hospital (1)
United States (12) · Spain (5) · Egypt (4) · Puerto Rico (4) · Australia (3) · Germany (3) · United Kingdom (3) · Belgium (2) · Canada (2) · China (2) · France (2) · Israel (2) · New Zealand (2) · Algeria (1) · Austria (1)
Eric Cohen, MD (4) · Daniel Cohen, MD (3) · Yan Luo, MD (3) · Dan Cohen, MD (2) · Isabelle A Gaultier, M.S., IBMH (2) · Roger Trinh, MD (2) · Adebayo A Lawal, MD (1) · Adebayo Lawal, M.D. (1) · Andrew Campbell, MD (1) · Andrew L Campbell, MD (1) · Armen Asatryan, MD (1) · Asem Elfert, Prof (1)
PMID 29377566, PMID 30739368, PMID 29909549, PMID 26321288, PMID 26596948, PMID 30291369, PMID 23281975, PMID 23439262, PMID 24428468, PMID 24720679, PMID 24720703, PMID 24818763, PMID 25386767, PMID 25451053, PMID 25644279, PMID 25839406, PMID 26100711, PMID 26147154, PMID 26248955, PMID 26710243, PMID 26711747, PMID 26743093, PMID 26778412, PMID 26976799, PMID 27084721, PMID 27115431, PMID 27762283, PMID 27919899, PMID 28404108, PMID 28412293, PMID 28842997, PMID 28865152, PMID 28941361, PMID 29180522, PMID 29535545, PMID 29546644, PMID 30160363, PMID 30853642, PMID 30858739, PMID 30868245, PMID 30980576, PMID 32356185, PMID 32406487, PMID 32451952, PMID 35174470, PMID 37671831, PMID 37771545
2014 (7), 2015 (4)